The Soothsayer announcements

  Scientists have proposed a new theory about the origins of Mars' moons, Phobos and Deimos. According to this theory, the moons may be the remains of an asteroid that was shredded by Mars' gravity. This theory could help explain the moons' unusual shapes and orbits. An upcoming mission to collect samples from Phobos may provide evidence to support or refute this theory. Forecast for 6 months: The Japanese space agency's Mars Moons Exploration mission is scheduled to launch in 2026, but it may be delayed due to unforeseen circumstances . This delay could push back the expected timeline for collecting samples from Phobos. Forecast for 1 year: The Mars Moons Exploration mission is expected to provide valuable insights into the origins of Phobos and Deimos. If the shredded asteroid hypothesis is supported, it could lead to a new understanding of how moons form around planets. Forecast for 5 years: The discovery of Phobos

  Partiful, a New York-based event-planning app, has been named Google's app of the year. Founded in 2020 by Palantir alums Joy Tao and Shreya Murthy, Partiful has gained popularity among Gen Z users for its user-friendly interface and features such as designing event pages, managing RSVPs, and tracking party invites. The app has seen significant growth, with 1.28 million downloads globally and a recent spike in weekly downloads. Forecast for 6 months: Partiful is expected to continue its growth trajectory , with a potential increase in monthly active users to 5-7 million. The app may also expand its features to include more integrations with popular calendar apps and social media platforms. Forecast for 1 year: Partiful is likely to become a household name , with a potential increase in downloads to 5-10 million. The app may also expand its user base to include more older demographics, leveraging its user-friendly interface and feature

  Eight biotech companies are making significant strides in breast cancer treatment, with innovative approaches and therapies showing promise in clinical trials. Arvinas, BioNTech, Carrick Therapeutics, Context Therapeutics, Hummingbird Bioscience, Oncolytics Biotech, Olema Pharmaceuticals, and Relay Therapeutics are among the companies pushing the boundaries of cancer treatment, offering new hope for patients and their families. In the next 6 months, we can expect to see more positive results from ongoing clinical trials, with several companies announcing promising data and potential breakthroughs in breast cancer treatment. Within the next year, we anticipate the approval of new therapies, such as Arvinas' ARV-471 and Oncolytics Biotech's pelareorep, which have shown significant promise in clinical trials and could become game-changers in the treatment of breast cancer. In the next 5 years, we expect to see a significant shift in